We market UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta® in the U.S., and CIMERLI™ (ranibizumab-eqrn) biosimilar of Lucentis® in the U.S. our Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) is approved in the U.S. and is expected to be available for patients in 2023.
Our strategy is to invest cash flows from our commercial biosimilar business to build an immuno-oncology franchise that will be synergistic with our proven commercial capabilities in oncology.
In 2021, we in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. A biologics license application for toripalimab for the treatment of nasopharyngeal carcinoma is under review by the FDA.
Our earlier-stage immuno-oncology pipeline includes CHS-006, a TIGIT-targeted antibody, being evaluated in a Phase 1/2 trial in combination with toripalimab in patients with advanced solid tumors. Coherus is discovering and developing additional immuno-therapies for cancer targeting novel pathways such as ILT4 and others.
